Walter Public Investments Inc. Has $2.88 Million Holdings in IDEXX Laboratories, Inc. $IDXX

Walter Public Investments Inc. lessened its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 48.7% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,116 shares of the company’s stock after selling 4,847 shares during the period. Walter Public Investments Inc.’s holdings in IDEXX Laboratories were worth $2,875,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Beacon Investment Advisory Services Inc. increased its holdings in IDEXX Laboratories by 11.9% in the fourth quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock worth $42,588,000 after purchasing an additional 6,710 shares in the last quarter. Nordea Investment Management AB boosted its holdings in shares of IDEXX Laboratories by 114.1% during the 4th quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock worth $11,283,000 after buying an additional 8,845 shares in the last quarter. Procyon Advisors LLC acquired a new stake in shares of IDEXX Laboratories during the 4th quarter worth approximately $1,966,000. Diversified Trust Co. grew its position in shares of IDEXX Laboratories by 223.5% during the 4th quarter. Diversified Trust Co. now owns 4,199 shares of the company’s stock worth $2,841,000 after buying an additional 2,901 shares during the period. Finally, Mirabella Financial Services LLP increased its stake in shares of IDEXX Laboratories by 156.2% in the 3rd quarter. Mirabella Financial Services LLP now owns 4,401 shares of the company’s stock valued at $2,806,000 after acquiring an additional 2,683 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on IDXX shares. Wall Street Zen upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, June 25th. Citigroup started coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target for the company. UBS Group dropped their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Finally, Stifel Nicolaus cut their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $557.80 on Friday. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 52 week low of $506.91 and a 52 week high of $769.98. The business has a 50 day moving average price of $555.31 and a 200-day moving average price of $609.16. The company has a market cap of $44.00 billion, a price-to-earnings ratio of 41.08, a P/E/G ratio of 3.05 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same period last year, the business earned $2.91 EPS. IDEXX Laboratories’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities analysts expect that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.